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Abstract
Objective: Few studies have assessed secular changes in the levels of cardiovascular risk factors (CV-RF) in populations of low
or middle income countries. The systematic collection of a broad set of both traditional and metabolic CV-RF in 1989 and 2004
in the population of the Seychelles islands provides a unique opportunity to examine trends at a fairly early stage of the
"diabesity" era in a country in the African region.
Methods: Two examination surveys were conducted in independent random samples of the population aged 25–64 years in
1989 and 2004, attended by respectively 1081 and 1255 participants (participation rates >80%). All results are age-standardized
to the WHO standard population.
Results: In 2004 vs. 1989, the levels of the main traditional CV-RF have either decreased, e.g. smoking (17% vs. 30%, p < 0.001),
mean blood pressure (127.8/84.8 vs. 130.0/83.4 mmHg, p < 0.05), or only moderately increased, e.g. median LDL-cholesterol
(3.58 vs. 3.36 mmol/l, p < 0. 01). In contrast, marked detrimental trends were found for obesity (37% vs. 21%, p < 0.001) and
several cardiometabolic CVD-RF, e.g. mean HDL-cholesterol (1.36 vs. 1.40 mmol/l, p < 0.05), median triglycerides (0.80 vs. 0.78
mmol/l, p < 0.01), mean blood glucose (5.89 vs. 5.22 mmol/l, p < 0.001), median insulin (11.6 vs. 8.3 μmol/l, p < 0.001), median
HOMA-IR (2.9 vs. 1.8, p < 0.001) and diabetes (9.4% vs. 6.2%, p < 0.001). At age 40–64, the prevalence of elevated total
cardiovascular risk tended to decrease (e.g. WHO-ISH risk score ≥10; 11% vs. 13%, ns), whereas the prevalence of the metabolic
syndrome (which integrates several cardiometabolic CVD-RF) nearly doubled (36% vs. 20%, p < 0.001). Data on physical activity
and on intake of alcohol, fruit and vegetables are also provided. Awareness and treatment rates improved substantially for
hypertension and diabetes, but control rates improved for the former only. Median levels of the cardiometabolic CVD-RF
increased between 1989 and 2004 within all BMI strata, suggesting that the worsening levels of cardiometabolic CVD-RF in the
population were not only related to increasing BMI levels in the interval.
Conclusion: The levels of several traditional CVD-RF improved over time, while marked detrimental trends were observed
for obesity, diabetes and several cardiometabolic factors. Thus, in this population, the rapid health transition was characterized
by substantial changes in the patterns of CVD-RF. More generally, this analysis suggests the importance of surveillance systems
to identify risk factor trends and the need for preventive strategies to promote healthy lifestyles and nutrition.
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Introduction
Cardiovascular disease (CVD) is leading the growing bur-
den of chronic noncommunicable diseases (NCD),
including in developing countries [1-3]. The good news is
that NCDs, and particularly CVD, are largely preventable
[4,5]. Large cohort studies conducted several decades ago
have shown that a large proportion of CVD events could
be attributed to three "classical" cardiovascular risk factors
(traditional CVD RF: tobacco smoking, raised blood pres-
sure, raised blood cholesterol) [6]. Recent evidence from
the INTERHEART study suggests that the relative risk of
CVD associated with these CVD RF is fairly constant
across populations [7], including in Africa [8].
Correspondingly, diet, physical activity and smoking are
key determinants of CVD and other NCDs [9]. For exam-
ple, the expected impact of combining not smoking, mod-
erate alcohol intake, regular physical activity, and high
intake of fruit and vegetables is a 80% reduction of both
CVD and all-cause mortality [10]. Furthermore, the clus-
tering of several risk factors of metabolic origin, which are
associated with unhealthy diet, lack of physical activity
and overweight, -e.g. increased triglycerides, decreased
HDL-cholesterol, impaired fasting glucose, hyperinsuline-
mia, diabetes- seems to increase vascular risk [11]. The so-
called metabolic syndrome is realized when several of
these factors are simultaneously present in the same indi-
vidual: this specific clustering apparently reflects a pro-
found metabolic dysfunction [12,13]. The frequency of
the metabolic syndrome seems to increase alongside the
worldwide raising prevalence of obesity.
The monitoring of population levels of the main CVD-RF
and related behaviors is the backbone for surveillance of
CVD and other NCDs [14,15]. However, reliable informa-
tion is limited in developing countries. While a number of
studies have reported the point prevalence of some CVD-
RF, few -if any- have provided population-based trends of
both traditional and cardiometabolic CVD-RF in the Afri-
can region. Such data are however crucial to characterize
epidemiological changes at population level [16] in order
to provide clues on the driving forces of the epidemic of
NCDs and to guide prevention and control strategies.
In this study, we report the 15-year trends of a broad set of
both the main traditional CVD-RF and several cardiomet-
abolic CVD-RF in the Seychelles, a rapidly developing
country in the African region, based on two comprehen-
sive population-based surveys in 1989 and 2004. Of note,
previous studies in this population had documented a
high CVD mortality [17], a high prevalence of peripheral
atherosclerosis [18] and high levels of traditional CVD-RF
[19,20]. The considered time interval may correspond to
a fairly early stage of the "diabesity" epidemic in a middle-
income country in epidemiological transition.
Methods
The Republic of Seychelles is a rapidly developing small
island state in the Indian Ocean (African region), east of
Kenya and north of Mauritius. The population size was
67'000 in 1989 (44% aged ≥25 years) and 84'000 in 2004
(57% aged ≥25 years), which reflects a rapid demographic
transition. This underlies the need for age-standardization
when comparing results over time. The majority of the
population is of African descent. Cardiovascular diseases
account for nearly 40% of total mortality [21]. Life expect-
ancy at birth increased from 63 to 69 years in men and
from 73 to 76 years in women between 1989 and 2004.
The gross domestic product (GDP) per capita rose, in real
terms, from $2927 in 1980 to US$ 5239 in 2004, driven
by booming tourism, industrial fishing and services.
Health care is available with no fee to all inhabitants
through a national health system.
Sampling frame of surveys
Independent population-based examination surveys of
CVD-RF were conducted in 1989 [19,22] and in 2004
[20,23]. For both surveys, the sampling frame consisted of
a random sex- and age-stratified sample of the population
aged 25–64 years. The samples were drawn from the pop-
ulation of the main island in 1989 (which accounts for
90% of the total population) and from the entire popula-
tion in several islands in 2004. Eligible individuals were
selected from an electronic database derived from popula-
tion censuses carried out in 1987 and 2002, regularly
updated thereafter by civil status authorities. In 1989,
1309 individuals we sampled; among them 58 were dead
or had emigrated at the time of the survey or could not be
traced, and 1081 participated in the survey (86.4%). In
2004, 1632 individuals were sampled; among them 37
were dead or had emigrated at the time of the survey and
32 could not be traced, and 1255 participated in the sur-
vey (80.2%). For both surveys, a letter was sent to the eli-
gible participants approximately two weeks prior the
appointments to invite them to attend the survey at spec-
ified study centers. Other dates for appointments could be
arranged and substantial efforts were made to trace the
non-participants (e.g. information in the mass media,
repeat invitation letters, phone calls, contacts through dis-
trict administrators, etc). Both surveys were conducted
under the auspices of the Ministry of Health, following
technical and ethical reviews. Participants gave oral
(1989) and written (2004) informed consent.
Measurement of lifestyle-related and clinical variables
In both surveys, trained officers administered a structured
questionnaire on demographic, lifestyle, and other varia-
bles to the participants using same or similar questions
with regards to the variables considered in this report.
Current tobacco use was defined as smoking at least one
cigarette every day. Alcohol intake was assessed from a setCardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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of questions on drinking frequency and volume for the six
main available alcoholic beverages (beer, wine/liquor,
spirits and three locally made homebrews), taking advan-
tage that only a limited number of brands and contents
were available in the country up to 2004. Questions on
alcohol were administered to all participants in 1989 but
only to the participants who reported to drink at least
once a month in 2004 (hence a slight underestimation of
alcohol intake in 2004 vs. 1989). Mean daily ethanol
intake was calculated. Definitions of "standard units" and
"sensible drinking" vary substantially across countries
(e.g. http://www.drinkingandyou.com/site/uk/biggy.htm
for definitions around the world). A standard unit most
often ranges from 8 to 14 g ethanol per day (or equiva-
lently 10–18 ml ethanol per day) and, in several coun-
tries, an intake of ethanol of approximately 1–29 ml/day
may correspond to "low risk"; 30–59 ml/day to "moder-
ate risk", and larger intake to "high risk".
Consumption of fruit and vegetables and physical activity
was assessed only in 2004 based on the standard STEPS
methodology for surveillance of chronic diseases [14,23].
The intake of fruit and vegetables was based on four ques-
tions. A daily intake of at least 5 portions of fruit and veg-
etables is recommended [14]. Physical activity was
assessed using the Global Physical Activity Questionnaire
(GPAQ), which includes 16 questions assessing the fre-
quency and intensity of physical activity at work, walking
to and from places (and not for leisure or work), and
physical activity at leisure time [14]. For the calculation, 4
and 8 MET were assigned to the time spent in moderate
and vigorous activities, respectively. Light, moderate and
high levels of physical activity were defined as <600, 600–
2999, and ≥3000 MET-minutes per week, respectively
[14].
Measurements of clinical variables were made in 1989
and 2004 using largely similar methods. Weight was
measured with calibrated medical electronic scales (Seca)
and height was measured using fixed stadiometers. Body
mass index (BMI) was calculated as weight divided by
squared height (kg/m2). Overweight, obesity and extreme
obesity were defined for BMI of 25–29, 30–39, and ≥40
kg/m2, respectively [24]. BP was measured with a mercury
sphygmomanometer using a cuff adapted to the arm cir-
cumference. BP was based on the two last of three read-
ings taken at intervals of at least 2 minutes, after the
participants had been quiet in the study center for at least
30 minutes and was seated for >10 minutes. Smoking was
not allowed in the study centers. We used the target of
<140/90 mmHg for "controlled" BP [25].
Measurement of biochemical variables
In both surveys, fasting blood was collected in the early
morning, blood was spun at the study centers, and serum
was immediately frozen to -20°C. For both surveys, par-
ticipants were requested, in their invitation letter, to fast
from midnight, except for water.
Except for blood glucose, all analyses were performed at
university laboratories in Switzerland. In 1989, total cho-
lesterol (TC) was measured enzymatically (CHOD-PAP
method) using reagents from Boehringer (Manheim, Ger-
many) and high density lipoprotein cholesterol (HDL-C)
was similarly measured in the supernatant after precipita-
tion of non HDL lipoproteins with phosphotungstate and
MgCl2. In 2004, blood lipids were measured using a
Hitachi 917 instrument and Roche reagents. Day-to-day
coefficients of variation (CV) were 2.6% for total choles-
terol, 4.1% for HDL-cholesterol, 4.8% for triglycerides in
1989, and 1,8%, 3.6%, and 4.5%, respectively, in 2004.
Low-density lipoprotein cholesterol (LDL-C) was calcu-
lated with the Friedewald formula. Total cholesterol ≥5.2
mmol/l (200 mg/dl) and ≥6.2 mmol/l (240 mg/dl)
defines "borderline high" and "high" levels, respectively
[26]. Total cholesterol ≥8.0 mmol/l (≥320 mg/dl) places a
person at high total CVD risk [27]. LDL-cholesterol ≥3.4
mmol/l (130 mg/dl) defines a "borderline high" level.
HDL-cholesterol <1.0 mmol/l (40 mg/dl) defines a "low"
level (i.e. a risk factor) and a value ≥1.5 mmol/l (60 mg/
dl) defines a "high" level (i.e. a preventive factor) [26].
Triglycerides ≥1.7 mmol/l (150 mg/dl) define a "border-
line-high" level [26].
Fasting blood glucose (FBG) was determined immediately
after blood drawing using point-of-care instruments. In
1989, measurements were made on venous blood using a
reflectance meter (Reflomat with Hemoglucotest reagent
strips, Boerhinger), a validated and frequently used gluco-
meter at the time, which adapts readings to plasma values
[28]. In case of elevated FBG and no diabetes history, a
second measurement was made 60–120 minutes later and
the last measurement was considered. In 2004, measure-
ments were made on venous blood using a Cholestec LDX
analyzer (Cholestec, Haywward, USA), a reliable alterna-
tive to conventional laboratory devices [29]; the instru-
ment separates blood cells from plasma and
measurements are made on plasma. Coefficients of varia-
tion for glycemia was 7.5% with Reflomat (1989) and
<4% with Cholestec LDX. In case of FBG and no diabetes
history, another measurement was carried out within 10
minutes on capillary blood (Ascentia Elite, Bayer) and the
mean of the two values was used. The Ascentia Elite par-
tially adjusts capillary blood readings to plasma values
[30]. Hence, although different instruments and
sequences were used, methods were fairly similar in 1989
and 2004, making a substantial systematic bias in results
in 2004 vs. 1989 unlikely. Impaired fasting blood glucose
was defined for FBG of 5.6–6.9 mmol/l (100 mg/dl-125Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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mg/dl) and diabetes for FBG ≥7.0 mmol/l (126 mg/dl),
along current recommendations [31].
Fasting serum insulin (FSI) was measured using commer-
cial radio-immuno assay (RIA) kits (1989: charcoal-
coated RIA; 2004: LINCO Research Inc, Missouri, USA).
Within-run and day-to-day CV were <6% in both 1989
and 2004. The RIA used in 1989 may overestimate insulin
concentration in individuals with high concentration of
proinsulin or proinsulin splits [32]. HOMA-IR (homeos-
tasis model assessment of insulin resistance) was calcu-
lated as [FSI (μU/ml) × FBG (mmol/l)]/22.5] [33] and has
been shown to be a reliable estimate of insulin resistance
both among diabetic and non diabetic subjects [34,35].
Cardiovascular disease risk prediction scores
We calculated different scores to estimate an individual's
total CVD risk: a) a simple combination of the main tra-
ditional CVD-RF (smoking, high BP and raised choles-
terol, or the same and diabetes) and b) the CVD risk
prediction score for the African region D (WHO/ISH risk
score). The WHO/ISH risk score was established by the
World Health Organization and the International Society
of Hypertension and it indicates the ten-year risk of a fatal
or non-fatal cardiovascular event (myocardial infarction
or stroke) according to age, sex, BP, smoking status, cho-
lesterol level and diabetes status [36,37]. We restricted all
score analyses to persons aged ≥40 years because the
WHO/ISH risk score is not designed for younger individ-
uals (the proportion of persons aged 40–64 in the popu-
lation of Seychelles constitutes nearly half of the
population aged 25–64). We defined the metabolic syn-
drome according to the updated ATP III criteria [38], how-
ever substituting obesity for increased waist
circumference, as we did not have waist circumference in
1989, and considering that a BMI ≥30 kg/m2 is a criterion
used in another definition of the metabolic syndrome
[39]. Based on data in 2004, the prevalence of the meta-
bolic syndrome using BMI ≥30 kg/m2  as a criterion
slightly underestimated the prevalence of the syndrome
using waist as a criterion (35.8% based on BMI ≥30 vs.
39.5% based on increased waist circumference, at age
≥40), and the agreement between the two definitions of
the metabolic syndrome was high (kappa was 97% in
men and 94% in women, p < 0.001).
Statistics
All prevalences, means and medians reported in this
report are weighted for age, separately for 1989 and 2004,
using the new World Health Organization standard pop-
ulation [40]. Results in 2004 vs. 1989 can therefore be
directly compared (i.e. differences do not reflect the
changing age structure of the populations between 1989
and 2004). Means are displayed for variables normally
distributed and medians for variables with skewed distri-
bution. Differences in means, medians and proportions
were tested with ANOVA, rank sum test and chi-square
test, respectively. Analyses were performed with Stata 8.2
and P values less than 0.05 were considered significant.
Results
Trends in conventional and cardiometabolic risk factors
Mean age of the participants (upon age standardization)
was 42 years (standard deviation: 11) for men and women
in both 1989 and 2004. Table 1 shows the trends in BMI,
smoking and alcohol intake between 1989 and 2004 as
well as the prevalence of categories of physical activity and
fruit and vegetable intake in 2004. Mean BMI was higher
in women than in men in both surveys and was markedly
higher in 2004 than in 1989 in both genders: in 2004,
52% of men and 68% of women were overweight or
obese. (BMI ≥25 kg/m2). The prevalence of cigarette
smoking decreased markedly (from 52% to 31% in men,
from 10% to 4% in women). Mean alcohol intake was
substantially lower in 2004 than in 1989. Homebrew
drinkers had higher ethanol intake from homebrews than
drinkers of commercial drinks had from commercial
drinks, and these mean alcohol intakes did not change
substantially between 1989 and 2004. However, the prev-
alence of drinkers of homebrews decreased markedly
between 1989 and 2004, which contributed to a large
decrease in total alcohol intake in 2004 vs. 1989. The
prevalence of men and women reporting the recom-
mended amount of ≥5 portions of fruit and vegetables per
day (in 2004) was very low. Approximately 80% of men
and women were classified as having either moderate or
high physical activity. However, the largest part of this
reported physical activity was related to physical activity at
work and only 41% of men and women reported physical
activity during their leisure time.
Table 2 shows changes in BP, blood lipids, fasting blood
glucose, diabetes, insulin and HOMA-IR between 1989
and 2004. Mean BP slightly decreased over time. The prev-
alence of persons taking antihypertensive treatment
increased greatly over time (from 9% to 24%). The preva-
lence of "hypertension" (BP ≥140/90 mmHg or taking
antihypertension treatment) was similar in 1989 and
2004). Mean serum total cholesterol levels, which were
substantially lower in men than in women in 1989,
increased largely over time in men, but only modestly in
women, resulting in almost identical levels in men and in
women in 2004. Almost two thirds of adults had elevated
or high total cholesterol levels (≥5.2 mmol/l) in 2004.
Mean HDL-cholesterol levels were higher in men than in
women in 1989. Serum HDL-cholesterol levels were
markedly higher in 2004 vs. 1989 in men, consistent with
increased prevalence of overweight and decreased alcohol
intake during the interval. Mean HDL-cholesterol levels
remained virtually unchanged in women. Consequently,Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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Table 1: Age-standardized trends in body mass index, smoking and alcohol consumption, 1989–2004, and categories of physical activity 
and fruit and vegetable intake in 2004
Men Women Total
Value 1989 2004 P 1989 2004 P 1989 2004 P
Body mass index (kg/m2)
mean (SD) 23.3 (3.7) 25.5 (4.7) *** 25.9 (5.7) 28.3 (6.3) *** 24.6 (5.0) 26.9 (5.7) ***
< 1 8 . 5 8 43 15 3
18.5–24.9 62 39 35 21 49 30
25.0–29.9 23 33 27 26 25 30
30.0–39.9 6 22 32 43 19 32
≥4 0 12 39 25
Daily cigarette smoking
Yes 50 36 *** 10 4 *** 30 17 ***
mean cig/day per smoker 12.7 30.8 * 6.9 8.1 ns 11.7 10.1 *
Alcohol intake (ml/day)
mean (SD) 71 (86) 40 (62) ** 9 (29) 4 (13) ** 40 (81) 22 (61) *
0 2 53 9 7 28 2 4 86 1
1–29 19 22 20 14 19 18
30–74 23 24 5 3 14 14
75–119 14 7 2 1 8 4
≥120 20 7 1 0 11 4
All alcoholic beverages
percent drinkers 75 61 *** 30 18 *** 52 39 ***
mean alcohol per drinker 94.8 65.9 *** 30.5 20.4 * 77.5 55.5 ***
Commercial alcoholic beverages
percent drinkers 71 58 *** 26 18 *** 49 38 ***
mean alcohol per drinker 40.1 41.7 ns 16.7 17.7 ns 33.7 36.2 ns
Homebrews
percent drinkers 37 12 *** 8 1 *** 23 6 ***
mean alcohol per drinker 114.7 135.4 ns 44.3 41.5 ns 104.8 126.1 ns
Fruit and vegetables (%)
<3 portions per day 65 63 64
3–4 portions per day 33 33 33
≥5 portions per day 2 4 3
Physical activity
Physical activity at work
percent reporting activitya 61 62 61
median MET-min/week 2880 2880 2880
Walking to places
percent reporting activitya 57 71 64
median MET-min/week 700 600 600
Physical activity during leisure time
percent reporting activitya 41 41 41
median MET-min/week 1200 600 720
Any physical activity (percent)
low (<600) 19 17 18
moderate (600–2999) 36 43 40
high (>3000) 45 40 42
Results are presented as percentage (prevalence), mean or median.
ns: not statistically significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
a report physical activity for at least 10 min at a time during on at least one day per week in the specified domain.Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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mean HDL-cholesterol levels became slightly higher in
women than in men in 2004. Median triglyceride levels
tended to increase over time (particularly in men). Mean
fasting blood glucose levels markedly increased between
1989 and 2004 both in men and women. Approximately
one third of men and women had impaired fasting blood
glucose levels in 2004 (i.e. FBG between 5.6 and 6.9
mmol/l). The prevalence of diabetes (FBG ≥7.0 mmol/l or
glucose lowering treatment) increased by approximately
50% between 1989 and 2004 (overall: 6.1% in 1989 to
9.4% in 2004). Median levels of fasting serum insulin and
HOMA-IR (which reflects insulin resistance) markedly
increased over time both in men and women.
The entire age-adjusted distributions of BMI, fasting insu-
lin and fasting glucose markedly shifted toward higher
values in 2004 vs. 1989 (Figure 1). There was a trend
towards a larger shift in the upper range than lower range
for BMI and insulin. For glucose, the shift seemed to be
larger for the lower than higher values of the distribution.
Table 2: Age-standardized trends in blood pressure, blood lipids, blood glucose, diabetes, insulin and HOMA-IR, 1989–2004
Men Women Total
1989 2004 P 1989 2004 P 1989 2004 P
BP (mmHg)
Systolic (mean) 133 (21) 131 (18) ns 127 (23) 124 (19) * 130 (22) 128 (19) **
Diastolic (mean) 87 (14) 85 (12) * 83 (14) 81 (13) ns 845 (14) 83 (12) *
< 1 2 0 / 8 0 2 11 9 3 44 0 2 83 0
120–139/80–89 35 42 33 35 33 38
140–159/90–99 25 25 21 16 23 21
160–169/100–109 17 12 10 8 14 10
≥180/110 2 2 2 1 2 1
≥140/90 or BP treatment 45 44 35 36 40 40
Medication for high BP
Yes 7 21 *** 11 26 *** 9 24 ***
Total cholesterol (mmol/l)
Mean 5.07 (1.10) 5.42 (1.26) *** 5.33 (1.18) 5.40 (1.20) ns 5.20 (1.14) 5.41 (1.26) ***
<5.2 60 50 48 49 55 48
5 . 2 – 6 . 1 3 02 8 2 92 8 2 92 9
6.2–7.9 9 20 20 20 15 20
≥8 . 0 1 23 32 3
HDL cholesterol (mmol/l)
Mean 1.43 (0.51) 1.35 (0.53) * 1.38 (0.36) 1.36 (0.41) ns 1.40 (0.44) 1.36 (0.47) *
<1.0 16 26 12 16 14 21
1 . 0 – 1 . 4 4 94 3 5 75 0 5 34 7
≥1 . 5 3 53 1 3 13 4 3 33 2
Triglycerides (mmol/l)
Median 0.81 0.90 ** 0.75 0.80 ns 0.78 0.80 **
>1.7 12 18 6 8 9 13
LDL cholesterol (mmol/l)
Mean 3.17 (1.09) 3.54 (1.25) *** 3.55 (1.10) 3.61 (1.16) ns 3.36 (1.11) 3.58 (1.20) ***
≥3 . 4 3 75 0 5 25 3 4 45 2
Fasting blood glucose (mmol/l)
Mean 5.21 (1.72) 6.03 (2.13) *** 5.24 (2.19) 5.75 (1.81) *** 5.22 (1.97) 5.89 ***
<5.6 76 60 78 73 77 67
5 . 6 – 6 . 9 1 83 1 1 61 9 1 72 5
≥7.0 5.9 9.2 5.8 7.9 5.8 8.5
≥7.0 or diabetes treatment 6.2 9.6 *** 6.2 9.1 *** 6.2 9.4 ***
Medication for diabetes
Yes 1.4 4.3 * 2.0 5.8 * 1.7 5.0 **
Fasting insulin (μmol/ml)
Median 6.8 10.5 *** 9.3 12.7 *** 8.3 11.6 ***
HOMA-IR
Median 1.6 2.7 *** 2.0 3.1 ** 1.8 2.9 ***
≥4.0 (upper quartile) 8 27 *** 13 33 *** 11 30 ***
Results are presented as percentage (prevalence), mean or median.
ns: not statistically significant; * p < 0.05; ** p < 0.01; *** p < 0.001.Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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Data are based on all participants, including those treated.
Of note, very few diabetic participants were treated with
insulin, and oral glucose lowering medications are
expected to only minimally lower glucose (e.g. by ~1–2
mmol/l) as compared to non-treated values. The fairly
similar shifts for the three cardiometabolic conditions
suggest that these three factors are strongly inter-related.
The proportionate changes in prevalences, in 2004 vs.
1989, were markedly different for the main traditional
CVD-RF vs. the cardiometabolic CVD-RF (Figure 2). For
the main three traditional CVD-RF, the prevalence either
decreased (smoking), did not substantially change
(hypertension, i.e. BP ≥140/90 or treatment), or slightly
increased (elevated cholesterol). In contrast, the propor-
tionate changes over time were largely unfavorable for
overweight and obesity, and for most of the considered
metabolic CVD-RF (low HDL-cholesterol, high triglycer-
ide, abnormal fasting glucose, upper quartile of HOMA-
IR). A larger relative increase in men than in women for
most of these obesity-related cardiometabolic CVD-RF is
consistent with the proportionately larger increase in
overweight/obesity in men than in women. Of note, the
absolute increase in mean BMI, between 1989 and 2004,
was similar in men (+2.2 kg/m2) and in women (+2.4 kg/
m2). However, because mean BMI was substantially lower
in men than in women in 1989 (with more women than
men being already overweight or obese in 1989), the pro-
portionate increase in the prevalence of overweight and
obesity, between 1989 and 2004, was greater in men than
in women. Of note, mean height changed by less than 0.2
cm between 1989 and 2004 both in men and women
aged 25–64 (P > 0.2), hence changes in BMI over time
almost entirely reflects increasing weight.
Trends in CVD prediction scores based on traditional and 
cardiometabolic risk factors
The age-standardized prevalence of categories with several
main traditional CV-RF among men and women aged 40–
64 years tended to decrease (although not significantly)
between 1989 and 2004 (Table 3). Similarly, the preva-
Age-standardized cumulative distribution of body mass index,  fasting insulin and fasting glucose in 1989 and 2004 Figure 1
Age-standardized cumulative distribution of body 
mass index, fasting insulin and fasting glucose in 1989 
and 2004.
Age-standardized proportionate changes in the prevalence of selected cardiovascular risk factors in 1989 and 2004 Figure 2
Age-standardized proportionate changes in the prevalence of selected cardiovascular risk factors in 1989 and 
2004.Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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lence of men and women with elevated total CVD risk,
based on the WHO/ISH risk score, tended to decrease
both in men and in women (except for women with a
score ≥20). In contrast, the prevalence of the metabolic
syndrome increased greatly in men (13% to 32%, P <
0.001) and in women (26% to 40%, P < 0.001).
Awareness, treatment and control rates for high blood 
pressure, diabetes and dyslipidemia
Awareness, treatment and control rates increased mark-
edly over time for high BP (Table 4). For diabetes, aware-
ness increased markedly, and almost all persons aware of
diabetes were treated in 2004, but the control rates among
treated persons remained low. For high cholesterol (data
available only in 2004), awareness and treatment
remained low in 1989 and 2004 but control was high
among the few persons treated (reflecting the high efficacy
Table 3: Age-standardized trends in the prevalence of cardiovascular risk prediction scores based on traditional and cardiometabolic 
risk factors, 1989–2004
Men Women Total
1989 2004 P 1989 2004 P 1989 2004 P
≥1 of 3 traditional risk factors 93 90 ns 83 81 ns 88 85 ns
≥2 of 3 traditional risk factors 55 47 ns 43 36 * 49 42 **
3 of 3 traditional risk factors 10 8 ns 2 1 * 6 5 ns
≥1 of 4 traditional risk factors 93 90 ns 84 82 ns 88 86 ns
≥2 of 4 traditional risk factors 57 51 ns 43 41 ns 50 46 ns
≥3 of 4 traditional risk factors 14 17 ns 10 10 ns 12 13 ns
4 of 4 traditional risk factors 3 2 ns 1 0 ns 2 1 ns
WHO/ISH score AFRO ≥ 10 14 11 ns 13 11 ns 13 11 ns
WHO/ISH score AFRO ≥ 2 0 75 n s 45 n s 65 n s
Metabolic syndrome 13 32 *** 26 40 *** 20 36 ***
ns: not statistically significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
DM: diabetes mellitus. WHO/ISH score AFRO: CVD risk prediction score for the African region D.
Major risk factors (3): blood pressure ≥140/90 mmHg or treatment; daily smoking; total cholesterol ≥5.2 mmol/l.
Major risk factors (4): same as above + diabetes (fasting blood glucose ≥7.0 mmol/l or treatment).
Metabolic syndrome using ATP III criteria modified with BMI ≥30 kg/m2 instead of elevated waist circumference.
Table 4: Age-standardized trends (in %) in awareness, treatment and control of high blood pressure, diabetes and 
hypercholesterolemia, 1989–2004
Men Women All
Aware among 
all with 
condition
Treated 
among 
aware
Controlled 
among 
treated
Aware 
among all 
with HBP
Treated 
among 
aware
Controlled 
among 
treated
Aware 
among all 
with HBP
Treated 
among 
aware
Controlled 
among 
treated
High blood pressure (BP ≥140/90 mmHg or treated)
1989 36 41 9 49 63 16 41 52 14
2004 55 89 24 75 96 42 64 93 34
P *** *** *** *** *** *** *** *** ***
Diabetes (fasting blood glucose ≥7.0 mmol/l or treated)
1989 36 64 28 44 75 24 40 70 26
2004 46 97 15 64 100 26 54 98 21
P ns ** ns * ** ns * *** ns
High total cholesterol (≥6.2 mmol/l or treated)
1989 - - - - - - - - -
2 0 0 4 9 2 47 81 12 84 21 02 65 7
ns: not statistically significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
Proportions (in %) are from total for "aware"; from aware for "treated", and from treated for "controlled".
Cut off values for "Controlled" are BP <140/90 mmHg for "high blood pressure", fasting blood glucose <7.0 mmol/l for "diabetes", and cholesterol 
<6.2 mmol/l for "high total cholesterol".Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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of atorvastatin, which was the lipid-lowering medication
used most often in the Seychelles in 2004).
Trends in traditional and cardiometabolic risk factors 
within BMI categories
Stratified analysis of CVD-RF levels within BMI categories
allows determining whether the secular changes in tradi-
tional and cardiometabolic CVD-RF in 2004 vs. 1989
were independent of the increase in BMI in the interval
(Table 5). All the considered traditional and metabolic
CVD-RF increased, as expected, across increasing catego-
ries of BMI. Within the same BMI categories, median
systolic and diastolic BP decreased over time (irrespective
of antihypertension medication) but the median levels of
several metabolic CVD-RF (particularly fasting blood glu-
cose and insulin) substantially increased over time, sug-
gesting a role of factors other than BMI to account for the
increasing levels of the cardiometabolic CVD-RF in 2004
vs. 1989.
Discussion
The major finding of this study is that the population lev-
els of the main traditional CVD-RF either decreased
(smoking, high blood pressure) or only slightly increased
(elevated total cholesterol) during the considered 15-year
interval, while the levels of several cardiometabolic CVD-
RF (diabetes, high triglyceride, low HDL-cholesterol, and
high HOMA-IR) markedly increased in a country in rapid
health transition in the African region. Correspondingly,
the prevalence of persons with elevated total CVD risk
(using a CVD risk prediction score largely based on the
main traditional CVD-RF) tended to decrease over time,
whereas the prevalence of the metabolic syndrome dou-
bled. These findings further suggest that the secular
increase in adiposity is driving secular changes in the car-
diometabolic risk profile in this population.
Several observations can be made in relation to the rather
favorable secular trends in several main traditional CVD-
RF. The large decrease in the prevalence of tobacco use
reflects sustained tobacco control programs during the
past decade in the Seychelles, including a ban on tobacco
advertisement, increasingly high taxes on cigarettes, and
continuous education programs in the mass media [41].
The slight secular downward trend in systolic/diastolic BP
is less easy to explain. While treatment and control rates
for hypertension markedly increased over time, and alco-
hol intake decreased, the prevalence of several other deter-
minants of high BP increased, e.g. overweight, insulin
resistance and, possibly, sedentary habits. A separate
study indicated moderate salt consumption in the Sey-
chelles (~5 grams per day) [42], consistent with a staple
diet based on fish and rice. Hence, protective, unac-
counted factors may override the impact of rising determi-
nants of BP.
The slight increase in total cholesterol and LDL-choles-
terol may relate to a shift from the traditional diet largely
made of rice and fish to increased consumption of meat
and processed foods. This deterioration in blood lipids
levels in the population is fairly small compared to other
developing countries [43]: this may relate to the already
fairly high cholesterol levels in the Seychelles in 1989 and,
perhaps, a shift toward an increasing consumption of veg-
etable oils low in saturated fats (e.g. corn oil) and a
decreasing consumption of palm oil (rich in saturated
fats), despite slightly higher prices of the former. This
might be attributable to health education programs in the
Seychelles, which have repeatedly emphasized on this
nutritional issue.
The largest secular change in CVD-RF was observed for
overweight and obesity. This is consistent with marked
socio-economic changes in the recent decades in the Sey-
chelles, including increased purchasing power (the GDP
Table 5: Age-standardized trends in median levels of traditional and cardiometabolic risk factors according to body mass index
BMI <25 BMI 25–29 BMI ≥30
1989 2004 P 1989 2004 P 1989 2004 P
Systolic BP (mmHg) 122 120 * 132 127 *** 138 131 ***
Diastolic BP (mmHg) 80 79 * 89 84 *** 90 86 ***
Systolic BP, not treated (mmHg) 120 118 *** 130 122 *** 134 126 ***
Diastolic BP, not treated (mmHg) 80 77 *** 87 81 *** 88 84 ***
LDL-cholesterol (mmol/l) 2.98 3.23 ** 3.66 3.61 ns 3.86 3.67 ns
HDL-cholesterol (mmol/l) 1.39 1.48 * 1.28 1.19 ns 1.24 1.19 ns
Triglyceride (mmol(l) 0.71 0.73 ns 0.93 0.94 ns 0.94 0.98 ns
Glucose (mmol/l) 4.6 5.2 *** 5.0 5.5 *** 5.2 5.6 ***
Insulin (μmol/l) 6.9 8.7 *** 9.7 12.8 *** 13.3 16.9 ***
All data are expressed as median values.
ns: not statistically significant; * p < 0.05; ** p < 0.001; *** p < 0.001.Cardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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per capita doubled in 2004 vs. 1989), larger caloric intake,
and increasing sedentary behaviors. For examples, calorie
availability per capita increased from 1800 to 2300 over
the past 20 years [44] and the local production of carbon-
ated soft drinks has tripled in the past 25 years (figures
from Seychelles Breweries Ltd). During the same period,
the numbers of private cars and passengers transported by
buses have doubled (figures from the Licensing Authority
and from the Seychelles Public Transport Company).
The association between adiposity, insulin resistance and
metabolic CVD-RF are well known [12,13]. We previously
showed that insulin resistance was associated with serum
triglycerides (directly) and HDL-cholesterol (inversely) in
the population of Seychelles [45]. We also described, in
this population, a high prevalence of the metabolic syn-
drome in 2004, irrespective of the definition used [46]; a
strong relationship between insulin resistance and BMI,
independent of blood glucose impairment [47]; and an
association between pre-diabetes and increased artery
intima-media thickness [48]. More generally, it is well rec-
ognized that the increasing prevalence of obesity is a main
driving force behind the rising prevalence of several cardi-
ometabolic CVD-RF, including insulin resistance and dia-
betes, in populations worldwide [11,49,50]. In our study,
the prevalence of overweight and obesity increased pro-
portionately more in men than in women, and so did the
levels of several cardiometabolic CVD-RF (although the
secular increase in mean BMI was similar, in absolute val-
ues, in both genders). This suggests that an increase in the
population levels of cardiometabolic CVD-RF may be
more sensitive to BMI changes at intermediary vs. high
levels. Interestingly, stratified analysis suggested that fac-
tors other than adiposity (as measured by BMI, in our
study) also accounted for the increasing levels of the car-
diometabolic CVD-RF over time.
What is the significance of our observed divergent secular
trends in traditional vs. cardiometabolic CVD-RF in the
population? Based on a review of all death certificates, the
age-adjusted mortality rates for stroke and myocardial inf-
arction (per 100'000 total population) were fairly high by
international standards, e.g. 92/69 in men/women for
stroke and 64/28 for myocardial infarction in 2002–2005
[17]. However, the rates in 2002–2005 were ~15–30%
lower than in 1989–1992 [17]. These downward CVD
mortality trends are consistent with decreasing levels of
several traditional CVD-RF and decreasing prevalence of
high total CVD risk (based on CVD risk prediction scores).
This also means that the detrimental trends in cardiomet-
abolic CVD-RF had little detrimental impact on CVD mor-
tality. This may relate to several factors. First, we
previously showed that the slope of the relationship
between BP and BMI had decreased in 2004 vs. 1989, irre-
spective of anti-hypertension treatment [51], suggesting a
secular decreasing impact of BMI on BP. Similarly, we
found that BP decreased during the past decade among
children despite a marked increase in the prevalence of
overweight [52]. A decreased impact of adiposity over
time has also been observed in other populations: both
the relative risk of CVD associated with obesity and the
mean levels of traditional CVD-RF within BMI strata
decreased over time (except for diabetes) in the USA
between 1970 and 2000 [53,54].
The discrepancy between the favorable trends in both
CVD mortality [17] and predicted CVD mortality (based
on the WHO/ISH risk score in this study), on one hand,
and the markedly unfavorable trends in cardiometabolic
CVD-RF, on the other hand, seems to dismiss a large
impact of the cardiometabolic CVD-RF (and insulin resist-
ance) on CVD outcomes, at a population level. There is
ongoing controversy on the value of the metabolic syn-
drome as a physiopathological and clinical concept able
to enhance our understanding and our management of
CVD risk in patients and in populations. It is not yet clear
whether the metabolic syndrome improves the prediction
of CVD risk as compared to traditional CVD-RF [55]; if it
predicts CVD incidence better than its individual compo-
nents [55-58]; or even if it performs better than fasting
blood glucose for predicting diabetes [58]. However, a
time lag may be necessary before this metabolic wave
translates into detrimental cardiovascular outcomes in the
population. This could explain why the decline in CVD
rates only recently flattened (among young adults) in
western countries, despite decades of increasing preva-
lence of obesity [59]. A time lag had also been suggested
for the effect of traditional CVD-RF on the incidence of
CVD [60]. Alternatively, a detrimental impact related to
the increased prevalence of several cardiometabolic CVD-
RF and, in particular, increasing insulin resistance in the
population might be offset, in our study, by the favorable
trends in several major traditional CVD-RF.
These uncertainties regarding the actual impact of obesity
and the metabolic syndrome on the incidence of CVD
should not lead to overlook the fully acknowledged link
between obesity and diabetes. The tide of diabesity is wor-
rying when considering the continuously poor control
rates among treated diabetic persons -in contrast to con-
trol of hypertension or dyslipidemia. This finding points
to the known difficulty to control cardiometabolic condi-
tions because of insulin resistance [61], a situation that
should likely result in an increased burden of diabetes-
related complications. The unfavorable impact of the ris-
ing levels of cardiometabolic CVD-RF on the burden of
diabetes-related diseases is illustrated, in the Seychelles,
by the increasing proportion of diabetic patients in
chronic hemodialysis (approximately a third of all
patients under chronic hemodialysis in 2004) and theCardiovascular Diabetology 2009, 8:34 http://www.cardiab.com/content/8/1/34
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increasing incidence of diabetes-related amputations
recorded at hospital.
There are a few limitations in the study. Laboratory meth-
ods were similar, but not identical, in 1989 and 2004,
which is inevitable since laboratory methods and instru-
ments change over time. However, except for blood glu-
cose, all biochemical analyses were done at university
laboratories using best practices at their time. Further-
more, the consistency in i) the observed secular detrimen-
tal changes for all the considered cardiometabolic CVD-
RF (e.g. HDL-cholesterol, triglyceride, glucose, insulin)
and ii) the good concordance between the proportionate
changes in the prevalence of obesity and the proportion-
ate changes in the mean levels of the considered cardi-
ometabolic CVD-RF in men vs. women, suggests
coherence in the results. From an epidemiological per-
spective, one must refrain to equate the category of "high
BP or treatment" (BP ≥140/90 mmHg or antihypertensive
treatment) to "hypertension", since BP measurements
based on only one occasion (like in our study) can sub-
stantially overestimate the true prevalence of hyperten-
sion [62]. The same remark applies, to a lesser extent, to
"elevated blood glucose or treatment" vs. "diabetes".
Strong points of the study include the fairly large sample
sizes, the truly random selection of the participants, the
large participation rates, the comprehensive assessment of
both traditional and cardiometabolic CVD-RF, the largely
similar methods used in the two surveys and, most impor-
tantly, the availability of such data in a country in the Afri-
can region as early as in 1989 (i.e. at a fairly early stage of
the diabesity era).
Our findings have several implications for public health.
Overall, the rather favorable secular trends in several main
traditional CVD-RF are consistent with the downward
trends in age-standardized CVD mortality in this popula-
tion [17]. This is consistent with downward age-specific
trends observed in the western countries [63] and -to a
lesser extent- in some developing countries as well [64].
The decreasing smoking prevalence and the improved
treatment rates for hypertension in Seychelles are likely
related to the national multipronged program against
chronic diseases since the early 1990s [41,65]. However,
the levels of these major traditional CVD-RF remain high
in the population. There is therefore a continued need for
public health interventions to further reduce levels of
smoking, BP and blood cholesterol in the population
[66,67] and for strengthening health services for
improved health care of high-risk individuals [68]. On the
other hand, the prevalence of obesity and related cardi-
ometabolic CVD-RF have dramatically increased during
the past 15 years, which may stem from global social and
economic changes that fuel unhealthy nutrition and phys-
ical inactivity [69]. The significance of these epidemiolog-
ical changes on the incidence of CVD cannot be evaluated
yet in our data – and further studies will be needed to
address this question-, but their impact on the prevalence
of diabetes and its complications is already visible. This
latter observation is the main reason to take the upward
trends in obesity and diabetes in developing countries as
a major public health challenge [70]. Since individual-
centered approaches for weight prevention and control
have limited impact [71], emphasis should be given to
policy and structural interventions that promote regular
physical activity and healthy nutrition in the entire popu-
lation [50,72-76]. Finally, our data emphasize the impor-
tance of reliable and standardized information systems to
identify the changing epidemiological situation and to
guide, monitor and evaluate the clinical and public health
responses.
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